Core Viewpoint - The company, Gucantang, has established compliance capabilities that meet the requirements for its upcoming IPO, demonstrating readiness for market entry [1][3]. Group 1: Compliance and Financial Metrics - Gucantang has fulfilled the core requirements for legal existence, stable main business operations, and no significant changes in core management, which are essential for IPO eligibility [1]. - The company can adapt its financial metrics to align with the specific standards of its target listing market, such as exceeding a cumulative net profit of 30 million yuan for the A-share market, or benefiting from profit exemption policies in the Hong Kong 18A sector [1]. Group 2: Core Competitiveness - Gucantang has established a robust patent protection system in the technology sector, with its self-developed enzyme conversion technology winning a national invention award, providing a differentiated competitive advantage for its market entry [1]. - The company has made significant technological breakthroughs in producing rare ginsenosides like Rh2, enhancing its adaptability for listing and injecting momentum into industry transformation [3]. Group 3: Sustainable Development - Gucantang has built a complete and independent production, procurement, and sales chain, demonstrating a clear and verifiable profit logic, with key operational indicators such as technology conversion efficiency and product repurchase rates showing positive trends [3]. - The company has effectively mitigated risks associated with over-reliance on policy support or single product operations, ensuring stability and sustainability in its business development [3].

Group 1 - The company, Gucantang, has met the basic compliance requirements for the listing process, including legal existence for over three years, stable main business operations, and no significant changes in core management [1] - Financially, Gucantang can adapt to different listing board requirements, such as exceeding a cumulative net profit of 30 million yuan for the A-share market, or opting for the Hong Kong 18A board which allows exemption from profit-related requirements [1] Group 2 - Gucantang has established a technological competitive edge with patented enzyme conversion technology, which has won a national technology invention award, and its industrial application capability is maturing, providing core support for its capital market ambitions [3] - The company has built a complete independent production, procurement, and sales system, demonstrating a clear and traceable profit logic, with indicators like improved technology conversion efficiency and stable product repurchase rates reflecting a healthy operational trend [3] - Gucantang's breakthroughs in the production of rare ginsenoside Rh2 through enzyme conversion not only advance industry development but also enhance its listing prospects, as companies with high purity and compliance qualifications are more likely to meet listing review requirements [3]